// App-Quantinova.ai

P160 : KEYNOTE-122: phase II study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma

Researchers

Presenter

  • Victor Lee

Principal Investigators

  • Roger K C Ngan

  • Anthony T C Chan

  • Ka Fai To

  • Myung Ju Ahn

  • Quan Sing Ng

  • Ruey-Long Hong

  • Jin-Ching Lin

  • Ramona F Swaby

  • Christine Gause

  • Sanatan Saraf

Medical Centers

  • National Cancer Centre Singapore, Singapore, Singapore

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Canada

  • Singapore

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Nasopharyngeal carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Capecitabine

  • Gemcitabine

  • Docetaxel

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved